Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator-Reference-Cited by-同舟云学术

Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator

Published:2008-04 Issue:2 Volume:8 Page:168-177
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Descotes Françoise,Riche Benjamin,Saez Simone,De Laroche Guy,Datchary Jean,Roy Pascal,André Jean,Bobin Jean Yves

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

2. Breast cancer: occurrence, risk factors and hormone metabolism;Sasco;Expert Rev Anticancer Ther,2003

3. Breast cancer metastasis: markers and models;Weigelt;Nat Rev Cancer,2005

4. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer;Goldhirsch;J Clin Oncol,2001

5. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer;Goldhirsch;J Clin Oncol,2003

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

;Cancer Management and Research;2019-12

2. Towards breast cancer targeting: Synthesis of tetrahydroindolocarbazoles, antibreast cancer evaluation, uPA inhibition, molecular genetic and molecular modelling studies;Bioorganic Chemistry;2019-12

3. Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors;Radiology and Oncology;2015-11-27

4. Post-operative nomogram for predicting freedom from recurrence after surgery in localised breast cancer receiving adjuvant hormone therapy;Journal of Cancer Research and Clinical Oncology;2014-11-30

5. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies;Breast Cancer Research;2014-08